S1209
Clinical - Urology
ESTRO 2026
median of PSA decreased from 32.3(28.9;43.1) to 0(0;0) ng/ml (Table 1).
Digital Poster 2016
The first results of high-risk prostate cancer patients’ hypofractionated radiotherapy with SBRT-boost Darya Mychko 1 , Anna Pumpur 1 , Marya Laptseva 1 , Stanislau Siamkouski 1 , Pavel Dziameshka 2 1 Radiotherapy, Minsk City Clinical Oncology Centre, Minsk, Belarus. 2 2Department of Radiation Therapy, N.N. Alexandrov National Cancer Centre, Lesnoy, Belarus Purpose/Objective: The purpose of the study is to evaluate the tolerability of an intensified radiotherapy course for high-risk prostate cancer (PCa) patients. Material/Methods: The prospective study enrolled the first 7 high-risk PCa patients underwent moderate hypofractionated radiotherapy (HFRT) follows the prostate SBRT- boost.Indications of this course were histologically confirmed high-risk PCa with a prostate volume ≤ 80 ml, bladder volume ≥ 100 ml, Karnofsky performance status ≥ 70%. In cases of seminal vessels and lymphnodes involvement, urethral stricture, a history of transurethral prostate resection and pelvic RT, severe urinary disorders, nonspecific inflammatory bowel diseases intensified RT was rejected.2 daily SBRT fractions with single dose of 7 Gy (PTV – prostate) was followed by 13 HFRT daily fractions with single dose of 3 Gy (PTV – prostate, seminal vessels and lymphnodes).Patients’ positioning accuracy was controlled with daily CBCT. During the SBRT-boost sessions target displacement was additionally tracked in a real-time with electromagnetic transmitter-based positioning system, during HFRT SGRT was used.Treatment tolerability assessment included determining the incidence and severity of early and late toxicity based on CTCAE5.0 and IPSS. PSA test and pelvic ultrasound data were also monitored. Indicators were controlled before and immediately after RT completed as well as 3, 6 and 12 months after treatment. Standard descriptive statistics was used to analyze the data. Results: By now 6 out of 7 patients underwent the treatment had follow-up ≥ 12 months, 1 patient – 9 months.The median of patients’ age at the time of RT was 73.1(66.0; 74.2) years. The median of prostate volume - 30.0(25.1; 40.6) ml, the median of PTV-boost volume - 48.4(40.7; 59.4) ml.Immediately after treatment course 6 patients noted only the symptoms of cystitis G1. In 3 months after RT 1 patient noted the symptoms of cystitis G1 and proctitis G1. In 6- and 12-month follow- up the patients didn't report any symptoms of bladder, intestinal or rectum toxicity, but urine tests revealed microhematuria in 1 patient.After RT the
According to pelvic ultrasound, no evidence of the PCa relapse was identified. Conclusion: HFRT with prostate SBRT-boost showed to be an effective option of high-risk PCa treatment. Comprehensive multimodality target positioning control allows for the high-risk PCa RT intensification without grade 2 or higher toxicity development. However, further research is needed to clarify the safety of this approach. Keywords: prostate cancer, SBRT Prospective Comparison of 5-Fraction SBPT and MR-Guided SBRT in High-Risk Prostate Cancer: One- Year Urinary Continence and Quality-of-Life Outcomes Darren MC Poon 1 , Oi Lei Wong 2 , Jing Yuan 2 , Bin Yang 3 , Sin Ting Chiu 4 , George Chiu 4 , Siu Ki Yu 3 1 Comprehensive Oncology Center, Hong Kong Sanatorium & Hospital, Hong Kong, Hong Kong. 2 Research Department, Hong Kong Sanatorium & Hospital, Hong Kong, Hong Kong. 3 Medical Physics Department, Hong Kong Sanatorium & Hospital, Hong Kong, Hong Kong. 4 Department of Radiotherapy, Hong Kong Sanatorium & Hospital, Hong Kong, Hong Kong Purpose/Objective: To prospectively compare two state-of-the-art ultra- hypofractionated modalities—stereotactic body proton therapy (SBPT) and MR-guided stereotactic body radiotherapy (MRgSBRT)—for high-risk prostate cancer, focusing on longitudinal, patient-reported quality of life (QoL). This represents one of the first direct clinical comparisons between image-guided particle therapy and MR-guided photon therapy, emphasizing urinary continence as a key functional endpoint. Material/Methods: In this prospective single-centre cohort (2022–2025), 70 consecutive high-risk patients received SBPT (n=31) or MRgSBRT (n=39). All patients were treated to the prostate in 5 fractions (SBPT: 38–40 Gy; MRgSBRT: 36.25–40 Gy), while elective pelvic lymphatic irradiation (25 Gy in 5 fractions) and intraprostatic Digital Poster Highlight 2059
Made with FlippingBook - Share PDF online